Cargando…
Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus
BACKGROUND: High costs of direct-acting antivirals (DAAs) have led health-care insurers to limit access worldwide. Using a natural experiment, we evaluated the impact of removing fibrosis stage restrictions on hepatitis C (HCV) treatment initiation rates among people living with human immunodeficien...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353326/ https://www.ncbi.nlm.nih.gov/pubmed/31504327 http://dx.doi.org/10.1093/cid/ciz833 |
_version_ | 1783557850029621248 |
---|---|
author | Saeed, Sahar Strumpf, Erin Moodie, Erica E M Wong, Leo Cox, Joseph Walmsley, Sharon Tyndall, Mark Cooper, Curtis Conway, Brian Hull, Mark Martel-Laferriere, Valerie Gill, John Wong, Alexander Vachon, Marie-Louise Klein, Marina B |
author_facet | Saeed, Sahar Strumpf, Erin Moodie, Erica E M Wong, Leo Cox, Joseph Walmsley, Sharon Tyndall, Mark Cooper, Curtis Conway, Brian Hull, Mark Martel-Laferriere, Valerie Gill, John Wong, Alexander Vachon, Marie-Louise Klein, Marina B |
author_sort | Saeed, Sahar |
collection | PubMed |
description | BACKGROUND: High costs of direct-acting antivirals (DAAs) have led health-care insurers to limit access worldwide. Using a natural experiment, we evaluated the impact of removing fibrosis stage restrictions on hepatitis C (HCV) treatment initiation rates among people living with human immunodeficiency virus (HIV), and then examined who was left to be treated. METHODS: Using data from the Canadian HIV-HCV Coinfection Cohort, we applied a difference-in-differences approach. Changes in treatment initiation rates following the removal of fibrosis stage restrictions were assessed using a negative binomial regression with generalized estimating equations. The policy change was then specifically assessed among people who inject drugs (PWID). We then identified the characteristics of participants who remained to be treated using a modified Poisson regression. RESULTS: Between 2010–2018, there were a total of 585 HCV initiations among 1130 eligible participants. After removing fibrosis stage restrictions, DAA initiations increased by 1.8-fold (95% confidence interval [CI] 1.3–2.4) controlling for time-invariant differences and secular trends. Among PWID the impact appeared even stronger, with an adjusted incidence rate ratio of 3.6 (95% CI 1.8–7.4). However, this increased treatment uptake was not sustained. At 1 year following universal access, treatment rates declined to 0.8 (95% CI .5–1.1). Marginalized participants (PWID and those of indigenous ethnicity) and those disengaged from care were more likely to remain HCV RNA positive. CONCLUSIONS: After the removal of fibrosis restrictions, HCV treatment initiations nearly doubled immediately, but this treatment rate was not sustained. To meet the World Health Organization elimination targets, the minimization of structural barriers and adoption of tailored interventions are needed to engage and treat all vulnerable populations. |
format | Online Article Text |
id | pubmed-7353326 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-73533262020-07-15 Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus Saeed, Sahar Strumpf, Erin Moodie, Erica E M Wong, Leo Cox, Joseph Walmsley, Sharon Tyndall, Mark Cooper, Curtis Conway, Brian Hull, Mark Martel-Laferriere, Valerie Gill, John Wong, Alexander Vachon, Marie-Louise Klein, Marina B Clin Infect Dis Articles and Commentaries BACKGROUND: High costs of direct-acting antivirals (DAAs) have led health-care insurers to limit access worldwide. Using a natural experiment, we evaluated the impact of removing fibrosis stage restrictions on hepatitis C (HCV) treatment initiation rates among people living with human immunodeficiency virus (HIV), and then examined who was left to be treated. METHODS: Using data from the Canadian HIV-HCV Coinfection Cohort, we applied a difference-in-differences approach. Changes in treatment initiation rates following the removal of fibrosis stage restrictions were assessed using a negative binomial regression with generalized estimating equations. The policy change was then specifically assessed among people who inject drugs (PWID). We then identified the characteristics of participants who remained to be treated using a modified Poisson regression. RESULTS: Between 2010–2018, there were a total of 585 HCV initiations among 1130 eligible participants. After removing fibrosis stage restrictions, DAA initiations increased by 1.8-fold (95% confidence interval [CI] 1.3–2.4) controlling for time-invariant differences and secular trends. Among PWID the impact appeared even stronger, with an adjusted incidence rate ratio of 3.6 (95% CI 1.8–7.4). However, this increased treatment uptake was not sustained. At 1 year following universal access, treatment rates declined to 0.8 (95% CI .5–1.1). Marginalized participants (PWID and those of indigenous ethnicity) and those disengaged from care were more likely to remain HCV RNA positive. CONCLUSIONS: After the removal of fibrosis restrictions, HCV treatment initiations nearly doubled immediately, but this treatment rate was not sustained. To meet the World Health Organization elimination targets, the minimization of structural barriers and adoption of tailored interventions are needed to engage and treat all vulnerable populations. Oxford University Press 2020-07-15 2019-08-28 /pmc/articles/PMC7353326/ /pubmed/31504327 http://dx.doi.org/10.1093/cid/ciz833 Text en © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Articles and Commentaries Saeed, Sahar Strumpf, Erin Moodie, Erica E M Wong, Leo Cox, Joseph Walmsley, Sharon Tyndall, Mark Cooper, Curtis Conway, Brian Hull, Mark Martel-Laferriere, Valerie Gill, John Wong, Alexander Vachon, Marie-Louise Klein, Marina B Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus |
title | Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus |
title_full | Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus |
title_fullStr | Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus |
title_full_unstemmed | Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus |
title_short | Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus |
title_sort | eliminating structural barriers: the impact of unrestricted access on hepatitis c treatment uptake among people living with human immunodeficiency virus |
topic | Articles and Commentaries |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353326/ https://www.ncbi.nlm.nih.gov/pubmed/31504327 http://dx.doi.org/10.1093/cid/ciz833 |
work_keys_str_mv | AT saeedsahar eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus AT strumpferin eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus AT moodieericaem eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus AT wongleo eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus AT coxjoseph eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus AT walmsleysharon eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus AT tyndallmark eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus AT coopercurtis eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus AT conwaybrian eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus AT hullmark eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus AT martellaferrierevalerie eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus AT gilljohn eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus AT wongalexander eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus AT vachonmarielouise eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus AT kleinmarinab eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus AT eliminatingstructuralbarrierstheimpactofunrestrictedaccessonhepatitisctreatmentuptakeamongpeoplelivingwithhumanimmunodeficiencyvirus |